Pegcetacoplan

Pre-clinicalActive

0 views this week 0 watching💤 Quiet

Interest: 24/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Geographic Atrophy

Conditions

Geographic Atrophy

Trial Timeline

Sep 28, 2023 → Jun 1, 2027

NCT ID

NCT06161584

About Pegcetacoplan

Pegcetacoplan is a pre-clinical stage product being developed by Apellis Pharmaceuticals for Geographic Atrophy. The current trial status is active. This product is registered under clinical trial identifier NCT06161584. Target conditions include Geographic Atrophy.

What happened to similar drugs?

1 of 12 similar drugs in Geographic Atrophy were approved

Approved (1) Terminated (3) Active (8)

🔄avacincaptad pegolAstellas PharmaPhase 3

✅avacincaptad pegolAstellas PharmaApproved

🔄Avacincaptad Pegol + ShamAstellas PharmaPhase 3

❌LampalizumabRochePhase 3

🔄Tinlarebant + PlaceboBelite BioPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04729062	Pre-clinical	Completed	—	—	C3G
NCT07020832	Phase 3	Recruiting	Feb 1, 2026	Aug 1, 2028	Delayed Graft Function
NCT06161584	Pre-clinical	Active	Sep 28, 2023	Jun 1, 2027	Geographic Atrophy
NCT05809531	Phase 3	Active	May 29, 2023	Jul 1, 2027	C3G
NCT05067127	Phase 3	Completed	Nov 12, 2021	Jan 14, 2025	C3G
NCT04572854	Phase 2	Active	Sep 7, 2021	Jan 1, 2026	C3G
NCT04901936	Phase 2	Recruiting	Feb 4, 2021	Dec 1, 2028	Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT03531255	Phase 3	Active	Aug 27, 2018	Jun 1, 2025	PNH
NCT03593200	Phase 2	Completed	Aug 16, 2018	Oct 22, 2019	PNH
NCT03465709	Phase 1/2	Terminated	Feb 14, 2018	Apr 5, 2019	Neovascular Age-related Macular Degeneration
NCT02588833	Phase 1	Completed	Dec 1, 2015	Aug 26, 2019	Paroxysmal Nocturnal Hemoglobinuria
NCT02503332	Phase 2	Completed	Sep 24, 2015	Jan 17, 2018	Geographic Atrophy
NCT02264639	Phase 1	Completed	Feb 23, 2015	Oct 22, 2018	Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT02461771	Phase 1	Completed	Jan 28, 2015	Mar 8, 2016	Neovascular Age-Related Macular Degeneration

Competing Products

20 competing products in Geographic Atrophy

See all competitors

Product	Company	Stage	Hype Score
avacincaptad pegol	Astellas Pharma	Phase 3	40
Avacincaptad Pegol	Astellas Pharma	Phase 2/3	38
avacincaptad pegol	Astellas Pharma	Approved	50
Avacincaptad pegol (ACP)	Astellas Pharma	Pre-clinical	33
Avacincaptad Pegol + Sham	Astellas Pharma	Phase 3	40
ABBV-6628 + SYFOVRE	AbbVie	Phase 1/2	39
FWY003 + Placebo	Novartis	Phase 2	42
CLG561 + LFG316 + Sham injection	Novartis	Phase 2	35
LFG316 + Sham + LFG316 Lower dose	Novartis	Phase 2	35
Lampalizumab	Roche	Phase 3	32
Lampalizumab	Roche	Phase 3	32
Lampalizumab	Roche	Phase 3	32
RO7669330 + Syfovre™ + Izervay™	Roche	Phase 1	36
RO7303359	Roche	Phase 1	29
SAR446597 + Sham Comparator	Sanofi	Phase 1/2	39
Pozelimab	Regeneron Pharmaceuticals	Phase 1	36
IONIS-FB-Lrx + Placebo (sterline saline 0.9%)	Ionis Pharmaceuticals	Phase 2	24
Tinlarebant + Placebo	Belite Bio	Phase 3	41
APL-2 + APL-2	Apellis Pharmaceuticals	Phase 3	34
APL-2, Pegcetacoplan	Apellis Pharmaceuticals	Phase 3	34